Fosun International Returns to Growth with 160% Profit Surge

The group’s revenue for the six-month period ending June 30 reached RMB86.96 billion. Despite ongoing divestments of non-core assets, the company maintained stability while significantly improving its operational health. Industrial operation profit rose 17% to RMB3.69 billion, a result Chairman Guo Guangchang attributed to years of systematic business streamlining and a disciplined focus on high-potential sectors including healthcare, insurance, and consumer tourism.

Fosun’s globalization strategy continues to anchor its financial performance, with overseas revenue hitting RMB49.16 billion, now accounting for more than 56% of total income. This international footprint is matched by a concerted push into innovation, where R&D spending jumped 16.7% to RMB4.2 billion. The pharmaceutical arm, Fosun Pharma, has successfully transitioned into a cycle of intensive approvals, securing 20 indications for seven innovative drugs. AI integration has further accelerated this pipeline, with the company utilizing proprietary platforms to shorten R&D lifecycles.

Financial stability remains a priority as the group navigates its growth phase. By offloading over RMB12 billion in non-strategic assets, Fosun lowered its total debt-to-capital ratio to 55.7%. With cash reserves exceeding RMB61 billion, the company is positioning itself to reclaim its annual profit targets. Looking ahead, leadership remains confident in returning to the RMB10 billion annual profit threshold, bolstered by a strengthened ESG profile that saw the firm reach an AAA MSCI rating.